An innovative initiative dedicated to start-ups Venn have introduced a new training initiative to help start-ups, at the beginning of their development, to fully benefit from our knowledge and expertise… read more →
On January 28th and 29th, Venn Life Sciences and its partner CEA (Pr. Daniel Gillet’s team) hosted a workshop gathering European experts on Hemolytic Uremic Syndrome caused by Shiga Toxin-producing… read more →
Venn Life Sciences Holdings Plc (“Venn” or the “Company”) Partnership Announcement Venn Life Sciences (“Venn”) an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial… read more →
Venn Life Sciences Holdings Plc (“Venn” or the “Company”) Strategic Collaboration Agreement with Open Orphan DAC and Financing Venn Life Sciences (“Venn”) an Integrated Drug Development Partner offering a combination… read more →
Venn Life Sciences Holdings Plc (“Venn” or the “Company”) Trading Update and Change of Adviser November 8, 2018 Venn Life Sciences (“Venn”) an Integrated Drug Development Partner offering a combination… read more →